SAB Biotherapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 9, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 9, 2025
SABS$3.07-1.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
| For The Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Revenue | ||
| Grant revenue | $— | $944,575 |
| Total revenue | — | 944,575 |
| Operating expenses | ||
| Research and development | 7,657,321 | 8,146,070 |
| General and administrative | 3,114,781 | 4,189,121 |
| Total operating expenses | 10,772,102 | 12,335,191 |
| Loss from operations | (10,772,102) | (11,390,616) |
| Other income (expense) | ||
| Changes in fair value of warrant liabilities | 5,035,769 | 5,468,219 |
| Interest expense | (69,565) | (76,371) |
| Interest income | 62,498 | 497,893 |
| Other income | 546,627 | 475,130 |
| Total other income | 5,575,329 | 6,364,871 |
| Net loss | $(5,196,773) | $(5,025,745) |
| Other comprehensive income (loss): | ||
| Unrealized loss, change in fair value of available-for-sale securities, net of tax | $(975) | $(56,061) |
| Foreign currency translation | 24,792 | (33,807) |
| Total comprehensive loss | $(5,172,956) | $(5,115,613) |
| Loss per common share attributable to the Company’s shareholders | ||
| Basic and diluted loss per common share | $(0.56) | $(0.54) |
| Weighted-average common shares outstanding – basic and diluted | 9,291,641 | 9,241,940 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.